Alena Zalutskaya

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Vivek Subbiah, Philippe A. Cassier, Salvatore Siena et al. · Nature Medicine · 2022 · 239 citations · Full text

Medicine, Oncology, Pharmacology +16

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Frank Griesinger, Giuseppe Curigliano, Michael Thomas et al. · Annals of Oncology · 2022 · 178 citations · Full text

Medicine, Oncology, Pharmacology +16

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 160 citations · Full text

Medicine, Oncology, Pharmacology +14

Phosphate-induced Apoptosis of Hypertrophic Chondrocytes Is Associated with a Decrease in Mitochondrial Membrane Potential and Is Dependent upon Erk1/2 Phosphorylation

Susanne U. Miedlich, Alena Zalutskaya, Eric D. Zhu et al. · Journal of Biological Chemistry · 2010 · 71 citations · Full text

Life Sciences, Biochemistry, Cell Biology +16

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Vivek Subbiah, Mimi I. Hu, Aaron S. Mansfield et al. · Thyroid · 2023 · 55 citations · Full text

Medicine, Oncology, Pharmacology +13